Interfraction interval in patients with stage III non-small-cell lung cancer treated with hyperfractionated radiation therapy with or without concurrent chemotherapy: Final results in 536 patients

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 27, Issue 6, 2004, Pages 616-625

  Jeremic, Branislav ^a,b   Milicic, Biljana ^a   Dagovic, Aleksandar ^a   Aleksandrovic, Jasna ^a   Milisavljevic, Slobodan ^a  

^a University Hospital   (Serbia)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Chemotherapy; Hyperfractionation; Interfraction interval; Non small cell lung cancer; Radiation therapy

Indexed keywords

CARBOPLATIN; ETOPOSIDE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESOPHAGUS DISEASE; FEMALE; HEMATOLOGIC DISEASE; HUMAN; LUNG DISEASE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PREDICTION; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; SKIN DISEASE; STATISTICAL SIGNIFICANCE; STOMACH DISEASE; TREATMENT OUTCOME;

EID: 10044220773     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.coc.0000138964.98445.c4     Document Type: Article

References (40)

1. Choi NCH, Doucette JA. Improved survival of patients with unresectable non-small cell bronchogenic carcinoma by an innovated high-dose en bloc radiotherapeutic approach. Cancer. 1981;48:101-109.
2. Perez C, Stanley K, Grundy G, et al. Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non-oat cell carcinoma of the lung. Cancer. 1982;50:1091-1099.
3. Perez CA, Pajak TF, Rubin P, et al. Long term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer. 1987;59:1874-1881.
4. Petrovich Z, Stanley K, Cox J, et al. Radiotherapy and the management of locally advanced lung cancer of all cell types. Final report of randomized trial. Cancer. 1981;48:1335-1340.
5. Cox JD, Azarnia N, Byhardt RW, et al. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60. O Gy to 79. 2 Gy: possible survival benefit with ≥69. 6 Gy in favorable patients with Radiation Therapy Oncology Group Stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11. J Clin Oncol. 1990;8:1453-1455.
6. Byhardt RW, Pajak TF, Emami B, et al. A phase I/II study to evaluate accelerated fractionation via concomitant boost for squamous, adeno, and large cell carcinoma of the lung: report of Radiation Therapy Oncology Group 84-07. Int J Radiat Oncol Biol Phys. 1993;26:459-468.
7. Mehta MP, Tannehill SP, Adak S, et al. Phase II trial of hyperfractionated accelerated radiation therapy for nonresectable non-small-cell lung cancer: results of Eastern Cooperative Oncology Group 4593. J Clin Oncol. 1998;16:3518-3523.
8. Saunders M, Dische S, Barrett A, Harvey A, Griffiths G, Parmar M (on behalf of the CHART Steering committee). Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee. Radiother Oncol. 1999; 52:137-148.
9. Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med. 1990;323:940-945.
10. Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage III non-small-cell lung cancer: Seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst. 1996;88:1210-1215.
11. LeChevalier T, Arriagada R, Lacombe-Terrier M-J, et al. Significant effect of adjuvant chemotherapy on survival in locally advanced non-small cell lung carcinoma [letter]. J Natl Cancer Inst. 1992;84:58.
12. Sause WT, Scott C, Taylor S, et al. Radiation Therapy Oncology Group 88-08 and Eastern Cooperative Oncology Group 4588: preliminary results of a phase III trial in regionally advanced, unresectable nonsmall cell lung cancer. J Natl Cancer Inst. 1995;87:198-205.
13. Sause W, Kolesar P, Taylor S IV, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer. Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest. 2000;117:358-364.
14. Jeremic B, Shibamoto Y, Acimovic L, et al. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol. 1995;13: 452-458.
15. Jeremic B, Shibamoto Y, Acimovic L, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: A randomized study. J Clin Oncol. 1996;14:1065-1070.
16. Schaake-Konig C, van der Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med. 1992;326:524-530.
17. Curran WJ Jr, Scott C, Langer C, et al. Phase III comparison of sequential vs concurrent chemoradiation for pts with unresected stage III non-small cell lung cancer (NSCLC): initial report of Radiation Therapy Oncology Group (RTOG) 9410 [Abstract 1891]. Proc Am Soc Clin Oncol. 2000;19:484a.
18. Furuse K, Nishikawa H, Takada Y, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999;17:2692-2699.
19. Furuse K, Hosoe S, Masuda N, et al. Impact of tumor control on survival in unresectable stage III non-small cell lung cancer (NSCLC) treated with concurrent thoracic radiotherapy (TRT) and chemotherapy (CT) [Abstract 1893]. Proc Am Soc Clin Oncol. 2000;19:484a.
20. Albain KS, Crowley JJ, Turrisi AT III, et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group Phase II study, SWOG 9019. J Clin Oncol. 2002;20:3454-3460.
21. Vokes EE, Herndon JE II, Crawford J, et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: Cancer and Leukemia Group B Study 9431. J Clin Oncol. 2002;20:4191-4198.
22. Lau D, Leigh B, Gandara D, et al. Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/ paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium phase II trial. J. Clin Oncol. 2001;19:442-447.
23. Jeremic B, Shibamoto Y, Milicic B, et al. Concurrent radiochemotherapy for patients with stage III non-small cell lung cancer (NSCLC). Long-term results of a phase II study. Int J Radiat Oncol Biol Phys. 1998;42:1091-1096.
24. Jeremic B, Shibamoto Y, Acimovic LJ, et al. Hyperfractionated radiation therapy and concurrent low-dose, daily carboplatin/etoposide with or without week-end carboplatin/etoposide chemotherapy in stage III non-small-cell lung cancer: a randomized trial. Int J Radiat Oncol Biol Phys. 2001;50:19-25.
25. Jeremic B, Shibamoto Y. Effect of interfraction interval in hyperfractionated radiotherapy with or without concurrent chemotherapy for stage III nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys. 1996;34:303-308.
26. Werner-Wasik M, Scott C, Graham ML, et al. Interfraction interval does not affect survival of patients with non-small cell lung cancer treated with chemotherapy and/or hyperfractionated radiotherapy: a multivariate analysis of 1076 RTOG patients. Int J Radiat Oncol Biol Phys. 1999; 44:327-331.
27. Shibamoto Y, Jeremic B, Acimovic LJ, et al. Influence of interfraction interval on the efficacy and toxicity of hyperfractionated radiotherapy in combination with concurrent daily chemotherapy in stage Ill nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys. 2001;50:295-300.
28. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for the Treatment and Research of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341-1346.
29. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998;338:1798-1804.
30. Jeremic B, Grujicic D, Antunovic V, et al. Hyperfractionated radiation therapy (HFX RT) followed by multiagent chemotherapy (CHT) in patients with malignant glioma. A phase II study. Int J Radiat Oncol Biol Phys. 1994;30:1179-1185.
31. Jeremic B, Shibamoto Y, Milicic B, et al. Hyperfractionated radiation therapy with or without concurrent low-dose cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol. 2000;18:1458-1464.
32. Wendt TG, Grabenbauer GG, Rodel CM, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol. 1998;16:1318-1324.
33. Rojas A, Joiner MC. The influence of dose per fraction on repair kinetics. Radiother Oncol. 1989;14:329-336.
34. Thames HD Jr, Withers HR, Peters JJ. Tissue repair capacity and repair kinetics deduced from multifractionated or continuous irradiation regimens with incomplete repair. Br J Cancer. 1984;49(suppl VI):263-269.
35. Cox JD, Pajak TF, Marcial VA, et al. ASTRO prenary: interfraction interval is a major determinant of late effects, with hyperfractionated radiation therapy of carcinomas of upper respiratory and digestive tracts: results from Radiation Therapy Oncology Group protocol 8313. Int J Radiat Oncol Biol Phys. 1991;20:1191-1195.
36. Fu KK, Pajak TF, Marcial VA, et al. Late effects of hyperfractionated radiotherapy for advanced head and neck cancer: long-term follow-up results of RTOG 83-13. Int J Radiat Oncol Biol Phys. 1995;32:577-588.
37. Bentzen SM, Saunders MI, Dische S. Repair halftimes estimated from observations of treatment-related morbidity after CHART or conventional radiotherapy in head and neck cancer. Radiother Oncol. 1999;53: 219-226.
38. Nelson DF, Curran WJ, Scott C, et al. Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma - possible advantage observed at 72.0 Gy in 1.2 b.i.d. fractions: report of the Radiation Therapy Oncology Group protocol 8302. Int J Radiat Oncol Biol Phys. 1993;25:193-207.
39. Jeremic B, Shibamoto Y, Milicic B, et al. Absence of thoracic radiation myelitis after hyperfractionated radiation therapy with and without concurrent chemotherapy for stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 1998;40:343-346.
40. Jeremic B, Shibamoto Y, Milicic B, et al. No thoracic radiation myelitis after spinal cord dose ≥ 50.4 Gy using 1.2. Gy b.i.d. fractionation in patients with stage III non-small-cell lung cancer treated with hyperfractionated radiation therapy with and without concurrent chemotherapy. Lung Cancer. 2002;35:287-292.